IMU-838 tablets

DRUG2 trials

Sponsors

Immunic AG

Conditions

Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting

Phase 3

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Active, not recruitingNCT05134441

Immunic AGMultiple Sclerosis

Start: 2021-11-18End: 2033-09-01Updated: 2026-02-23

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Active, not recruitingNCT05201638

Immunic AGMultiple Sclerosis, Relapsing-Remitting

Start: 2022-01-12End: 2033-10-01Updated: 2026-02-23

Related Papers

Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Neurology Neuroimmunology & Neuroinflammation2024-04-2510 citations